Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Silence Therapeutics (SLN) Restructuring Costs (2025)

Silence Therapeutics (SLN) has disclosed Restructuring Costs for 1 consecutive years, with -$24000.0 as the latest value for Q4 2025.

  • Quarterly Restructuring Costs changed N/A to -$24000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.3 million through Dec 2025, changed N/A year-over-year, with the annual reading at $1.3 million for FY2025, N/A changed from the prior year.
  • Restructuring Costs hit -$24000.0 in Q4 2025 for Silence Therapeutics, down from $1.3 million in the prior quarter.
  • In the past five years, Restructuring Costs ranged from a high of $1.3 million in Q2 2025 to a low of -$24000.0 in Q4 2025.